Omar H. Butt
YOU?
Author Swipe
View article: Diffusely metastatic glioblastoma with FGFR3::TACC3 fusion: cell-free DNA fragmentation analyses and molecular characterization of matched primary and metastatic tumor sites
Diffusely metastatic glioblastoma with FGFR3::TACC3 fusion: cell-free DNA fragmentation analyses and molecular characterization of matched primary and metastatic tumor sites Open
View article: 490 Laser interstitial thermal therapy plus pembrolizumab extends survival and ignites anti-tumor immunity in recurrent high-grade astrocytoma: results from a phase 1/randomized phase 2b trial
490 Laser interstitial thermal therapy plus pembrolizumab extends survival and ignites anti-tumor immunity in recurrent high-grade astrocytoma: results from a phase 1/randomized phase 2b trial Open
View article: Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma
Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma Open
Purpose Recent studies show that glioblastoma (GBM) is more sensitive to temozolomide (TMZ) in the morning. In cells, inhibiting O6-Methylguanine-DNA-Methyltransferase ( MGMT ) abolished time-dependent TMZ efficacy, suggesting that circadi…
View article: A phase I window-of-opportunity study of neoadjuvant avelumab and hypofractionated radiation therapy in radiation-relapsed meningioma
A phase I window-of-opportunity study of neoadjuvant avelumab and hypofractionated radiation therapy in radiation-relapsed meningioma Open
Effective treatments for recurrent, radiation-relapsed meningiomas (RR-meningiomas) following surgery and radiation therapy (RT) are limited. Inhibitors of the programmed-death-1 (PD-1) or programmed-death ligand-1 (PD-L1) pathway have sho…
View article: Circadian variation in MGMT promoter methylation and expression predicts sensitivity to Temozolomide in glioblastoma
Circadian variation in MGMT promoter methylation and expression predicts sensitivity to Temozolomide in glioblastoma Open
Purpose Recent studies show that glioblastoma (GBM) is more sensitive to Temozolomide (TMZ) in the morning. In cells, inhibiting O6-Methylguanine-DNA-Methyltransferase (MGMT) abolished time-dependent TMZ efficacy, suggesting that circadian…
View article: Eccrine carcinomas and homologous recombination repair cancer predisposition genes: A case series
Eccrine carcinomas and homologous recombination repair cancer predisposition genes: A case series Open
View article: Tracking Daily Variations in Rest-Wake to Guide Personalized Timing of Temozolomide for High-Grade Glioma Patients
Tracking Daily Variations in Rest-Wake to Guide Personalized Timing of Temozolomide for High-Grade Glioma Patients Open
High-grade gliomas, like glioblastoma multiforme (GBM), are the most common malignant brain tumors in adults and are treated with the chemotherapy drug temozolomide (TMZ). In humans, a retrospective analysis of patients’ overall survival s…
View article: Sociodemographic factors predict outcomes and reveal spatial tumor patterns in glioblastoma
Sociodemographic factors predict outcomes and reveal spatial tumor patterns in glioblastoma Open
Background Glioblastoma (GBM) is the deadliest malignant glioma of the central nervous system. Postsurgical functional impairment correlates with survival and is estimated using metrics such as extent and location of resection. This study …
View article: Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma Open
View article: Predicting post-surgical functional status in high-grade glioma with resting state fMRI and machine learning
Predicting post-surgical functional status in high-grade glioma with resting state fMRI and machine learning Open
View article: Case report: Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma
Case report: Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma Open
Immunotherapy is the first-line option for treating advanced cutaneous squamous cell carcinoma (cSCC). However, up to half of patients experience no benefit and treatment resistance, warranting newer therapeutic approaches. Combinatory app…
View article: Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification
Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification Open
View article: Evolving Barriers to Clinical Trial Enrollment and Clinical Care in Neuro-oncology in the Face of COVID-19
Evolving Barriers to Clinical Trial Enrollment and Clinical Care in Neuro-oncology in the Face of COVID-19 Open
The lack of treatments with durable response in neuro-oncology highlights the critical need for clinical trials to advance patient care. The intersection of relatively low incidence, evolving classification schema, and entrenched community…
View article: Cross‐sectional comparison of the role of tau burden among Down Syndrome Alzheimer disease and autosomal‐dominant Alzheimer disease
Cross‐sectional comparison of the role of tau burden among Down Syndrome Alzheimer disease and autosomal‐dominant Alzheimer disease Open
Background Adults with Down Syndrome (DS) develop Alzheimer disease (AD)‐like pathology and dementia as they age. This is attributed to triplication of the amyloid precursor protein gene. Recent work demonstrated that amyloid is elevated i…
View article: The gut microbiome as an early biomarker of preclinical Alzheimer disease
The gut microbiome as an early biomarker of preclinical Alzheimer disease Open
Background The current paradigm of Alzheimer disease (AD) pathology teaches that people progress from cognitive normality, to cognitive normality with biomarker evidence of disease (preclinical AD), and ultimately to symptomatic AD with co…
View article: CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB
CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB Open
GBM AGILE (NCT03970447;https://www.gcaresearch.org/research/gbm-agile) is a phase 3 Bayesian adaptive platform trial that efficiently tests multiple arms against common control, with 6 arms included to date. Primary endpoint is overall sur…
View article: Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma
Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma Open
Oligometastatic progression represents a unique manifestation of tumor immune-escape that can lead to disease progression during treatment with immune checkpoint inhibitor (ICI). The diagnosis and further optimal management of oligometasta…
View article: PARP inhibition and immunotherapy: a promising duo in fighting cancer
PARP inhibition and immunotherapy: a promising duo in fighting cancer Open
View article: BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series
BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series Open
Targeted and immune therapies have changed the paradigm of treatment for patients with metastatic melanoma. Treatment of patients with symptomatic melanoma brain metastases, however, is complicated by the frequent use of immune suppression…
View article: Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19 Open
Importance Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking. Objective To assess the association between anticancer therapy exposure within 3 months prio…
View article: Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of Heterozygosity
Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of Heterozygosity Open
There is a lack of effective treatments for immunotherapy-refectory melanoma. Although PARP inhibitors (PARPi) are an effective treatment strategy in cancers with homologous recombination deficiency (HRD), determining HRD status is challen…
View article: Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
Homologous Recombination Deficiency (HRD) in Cutaneous Oncology Open
Skin cancers, including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (SCC), and melanoma, are the most common malignancies in the United States. Loss of DNA repair pathways in the skin plays a significant role in tumorigen…
View article: Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease
Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease Open
Alzheimer’s disease (AD) pathology is thought to progress from normal cognition through preclinical disease and ultimately to symptomatic AD with cognitive impairment. Recent work suggests that the gut microbiome of symptomatic patients wi…
View article: Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer’s and coronary disease pathways
Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer’s and coronary disease pathways Open
View article: A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome Open
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the management of several life-threatening malignancies, often achieving durable sustained responses. The number of patients treated with this new class of cell-based therap…
View article: A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastoma
A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastoma Open
Background Myeloid-derived suppressor cells (MDSCs) are critical regulators of immunosuppression and radioresistance in glioblastoma (GBM). The primary objective of this pilot phase Ib study was to validate the on-target effect of tadalafi…
View article: Proteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression
Proteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression Open
Heterogeneity in progression to Alzheimer's disease (AD) poses challenges for both clinical prognosis and clinical trial implementation. Multiple AD-related subtypes have previously been identified, suggesting differences in receptivity to…
View article: Corrigendum: Identification and management of aggressive meningiomas
Corrigendum: Identification and management of aggressive meningiomas Open
[This corrects the article DOI: 10.3389/fonc.2022.851758.].
View article: Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study Open
View article: Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios
Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios Open
Circulating-tumor DNA (ctDNA) has emerged as an important biomarker for monitoring disease status in cancer patients. Different ctDNA testing platforms have shown promising results in the early detection of disease, monitoring response to …